RealMove (Lung): Assessing Tumour Motion With Dynamic MRI

Status Recruiting

Clinical Trial Summary

The study aims to develop an improved method to tailor the geometric safety margin when treating with stereotactic body radiotherapy (SBRT), to avoid tumour cells being missed during irradiation and to limit the exposure of normal tissues as much as possible. Dynamic magnetic resonance imaging (MRI) is assumed to represent the tumour motion during the respiratory cycle more realistically, compared to 4-dimensional computed tomography (4D CT), thanks to its high temporal resolution and the possibility to image the motion over a longer period of time. Patients receiving SBRT for a pulmonary target located below the level of the carina are included in the study, and the hypothesis will be tested through a comparison of the tumour amplitude measured with each modality. Furthermore, the predictive value of the image series acquired at treatment planning, for the motion patterns observed at each treatment fraction, will be evaluated through repeated 4D CBCT acquisitions.

Clinical Trial Description

In the current study, a 2D-cine MRI examination will be performed, in addition to the 4D CT examination that is standard for patients receiving radiotherapy for tumours in the thorax or abdomen. A subgroup of the study participants (referred to as the 4D CBCT subcohort) will also be required to perform a 4D CBCT examination at three treatment sessions. The main cohort consists of 95 subjects and the 4D CBCT subcohort of 55 subjects. The study does not involve any change in the treatment routine; rather, the study images are collected for retrospective analysis. Following each imaging session, the subject should fill out an anxiety questionnaire and their pulse will be measured, to give an indication of any anxiety which might influence the breathing pattern of the current session. Clinical follow-up will be performed retrospectively by reviewing the participants' medical records. Progress, health status and treatment-related toxicity will be evaluated, up to 10 years after completed treatment. The study objectives are: - To evaluate dynamic MRI for characterising the respiratory-related tumour motion, compared to the current standard modality of 4D CT. - To evaluate the variation in breathing motion at different times points. - To evaluate the clinical outcome. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06322329
Study type	Interventional
Source	Region Stockholm
Contact	Mattias Hedman, MD PhD
Phone	+46812370000
Email	mattias.hedman@regionstockholm.se
Status	Recruiting
Phase	N/A
Start date	March 15, 2024
Completion date	March 17, 2036

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02939729` - Physiotherapy Prehabilitation in Patients Undergoing Cardiac or Thoracic Surgery	N/A
Completed	`NCT02559349` - Gut Microbiota And Radiotherapy
Completed	`NCT02862288` - Preliminary Study of Microwave Tumoral Ablation Performances for the Treatment of Pulmonary, Renal and Bone Neoplasia.	Phase 1/Phase 2
Recruiting	`NCT04056273` - Assess the Use of rEBUS With a Guide Sheath to Increase Transbronchial Lung Biopsy Yield Rate	N/A
Recruiting	`NCT03528733` - Feasibility of Multi-Energy Digital Radiography Detector for Lung Lesions Detection	N/A
Completed	`NCT03972228` - Microdevice for Evaluating Drug Response in Site in Lung Lesions	Early Phase 1
Not yet recruiting	`NCT06397807` - Postoperative Pain Management on Patients Undergoing Lung Tumor Resection
Withdrawn	`NCT04917224` - Study of LUNG Stereotactic Adaptive Ablative Radiotherapy	N/A
Active, not recruiting	`NCT03881410` - The Efficacy of Shear-wave Elastography-guided Aspiration and Biopsy for Diagnosis in Lung Tumor	N/A
Not yet recruiting	`NCT05279521` - The Effect of Interventional Pulmonary Rehabilitation Exercise With Advanced Lung Cancer.	N/A
Active, not recruiting	`NCT05169437` - Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors	Phase 2
Completed	`NCT01394978` - NeoMend ProGEL™ Pleural Air Leak Sealant Post-Approval Study	N/A
Recruiting	`NCT04974632` - Mobile 3D C-arm CT for Lung Tumor Localization Efficacy Analysis: a Prospective Clinical Trial	N/A
Active, not recruiting	`NCT05555342` - A Novel Method for Treating Lung Met w/Combo of Electric Fields & Rad Therapy: A Single-Arm	Early Phase 1
Completed	`NCT01388803` - The Depth of Right Bronchial Blocker Placement in Taiwanese in Video-assisted Thoracoscopic Surgery(VATS)	N/A
Completed	`NCT03645915` - GLUT1: A Novel Tool re fl Ecting Proliferative Activity of Lung Neuroendocrine Tumors
Recruiting	`NCT04075305` - The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

RealMove (Lung): Assessing Tumour Motion With Dynamic MRI — RealMove(lung)

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms